Doxorubicin (DOX) is a widely-used effective antitumor agent. However, its clinical application is limited due to its side effects including anti-apoptotic defense of cancer cells caused by DOX-induced autophagy and deleterious effects in normal tissues. Therefore, in this study, a new folate (FA)-decorated amphiphilic bifunctional pullulan-based copolymer (named as FPDP) was developed as an efficient nano-carrier for the co-delivery of DOX and short hairpin RNA of Beclin1, a pivotal autophage-related gene, to enhance the anticancer effect of DOX by the blockade of the Beclin1 protein mediated autophagy process. In FPDP molecules, pullulan was modified with lipophilic desoxycholic acid for the formation of micelles, the introduced low molecular weight (1 kDa) branched polyethylenimine (PEI) was for shBeclin1 delivery, 
Introduction
DOX is a leading, clinically used anticancer drug owing to its potency and broad spectrum of activity against diverse cancer types.
1 However, its clinical therapeutic efficacy is greatly limited by its diverse toxicities to normal tissue, such as severe cardiotoxicity, 2 and efflux pump-mediated or non-pump-related multi-drug resistance (MDR). During chemotherapy, the nonpump-related MDR which decreases the sensitivity of cancer cells to chemotherapeutic drugs has been predominantly attributed to the activation of anti-apoptotic cellular defense pathways. 3 The autophagy, an evolutionarily conserved and selective degradation process of cellular components, can maintain energy production for cell survival under limited nutrient or toxic stimuli conditions. 4, 5 In many cancer cells, the autophagy process is reported to cause non-pump-related MDR, resulting in unsatisfactory chemotherapeutic effects with single drugs. 6, 7 Thus, it is universally accepted that autophagydependent survival should be blocked to promote tumor-cell death. 8 The autophagy process in tumor cells is a complicated biological process with a series of genes and mechanisms involved. Beclin1, as an autophagy-related gene, plays a vital role in autophagy activation by regulating the nucleation of autophagic vesicles. 9, 10 It has been revealed that Beclin1 is activated in the autophagy process and induces the occurrence of resistance mechanisms in chemotherapy. RNA interference (RNAi), a promising approach in cancer therapy, can selectively down-regulate relevant gene expression, overcome the multidrug resistance and improve the efficiency of chemotherapeutic drugs. [11] [12] [13] [14] RNAi is oen mediated by short hairpin RNAs (shRNA) or small interfering RNAs (siRNA). The shRNA is a sequence of RNA which makes a tight hairpin turn and can be cloned into expression vectors to ensure that the shRNA is always expressed. Daniel et al. 15 reported that partial Beclin1 silencing aggravates DOX and Fas induced apoptosis in HepG2 cells, demonstrating that selectively down-regulating Beclin1 gene expression can overcome the multi-drug resistance, and improve the sensitivity of cancer cells to DOX. However, in the research of Daniel's group, the silencing of Beclin1 gene expression and DOX treatment was administrated separately, and the therapeutic efficacy of DOX may be reduced. In this contribution, a nanocarrier-based delivery system offers a platform for the co-delivery of siRNA (shRNA) and anticancer chemotherapeutics simultaneously to the same tumor cells. 16 In recent years, enormous efforts have been put into the development of novel siRNA (shRNA) and DOX co-delivery systems with enhanced bioavailability, low toxicity and prolonged circulation time, such as polymers, 11, 17 liposomes, 18 dendrimers, 19 mesoporous silica nanoparticles 13, 20, 21 and quantum-dot (QD)-based nanoparticles.
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Among those systems, the amphiphilic cationic copolymers are widely used due to their excellent biocompatibility, desirable biodegradability, and unique self-assembling property. In general, the amphiphilic cationic copolymers can form core-shell structured micelles with a hydrophobic core and a hydrophilic shell of positive charge in aqueous solution, loading the hydrophobic antitumor drugs and polyanionic genes in single carrier. 23, 24 For instance, Chen et al. reported that FR-targeted multifunctional micelleplexes based on FA conjugated to poly(ethylene glycol)-block-poly(glutamic acid) (FA-PEG-PGA) loaded with Bcl-2 siRNA and DOX demonstrated a synergistic therapeutic effect in inhibiting the growth of C6 glioma in rats. 25 A hyaluronic aciddecorated polyethylenimine-poly (D,L-lactide-co-glycolide) (PEI-PLGA) nanoparticle system was developed by Wang and coworkers for the co-delivery of DOX and miR-542-3p for triple negative breast cancer (TNBC) therapy and demonstrated improving antitumor efficacy.
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Pullulan, a natural non-ionic and linear homopolysaccharide, has attracted increasing attention in wide pharmaceutical and biomedical applications such as platform materials for drug and gene delivery systems due to its excellent biocompatibility, low viscosity and desirable water solubility. [27] [28] [29] In our previous study, an amphiphilic polymer (named as PDP) was synthesized by linking lipophilic desoxycholic acid (DA) and low molecular weight (1 kDa) branched polyethylenimine (PEI) with pullulan (P). Herein, the amphiphilic polymer self-assembled into micelles with positively-charged PEI located on the hydrophilic shell to bind negatively charged genes through electrostatic interactions, and DA in the hydrophobic core to encapsulate hydrophobic anticancer drugs via hydrophobic interaction. PDP micelles could co-deliver tumor suppressor p53 gene and anticancer drug DOX, exhibiting effective antitumor efficacy in vitro and in vivo. 30 Based on this encouraging results, in the present work, we modied PDP polymers with FA further to synthesize a new FR targeted pullulanbased copolymer (FPDP) (Scheme 1) and developed it as a FRtargeted micellar platform for cellular co-delivery of shBeclin1 and DOX to improve the anticancer effect of DOX through the blockade of autophagy process. The FR, a high affinity membrane Scheme 1 Synthesis scheme of FPDP and illustration of tumor targeting strategy of FPDP nano-micelles for the simultaneous co-delivery of drug and shRNA into cancer cells.
protein, is overexpressed in a wide variety of human tumors including more than 90% of ovarian carcinomas. 31 Additionally, the expression level of FR in normal tissues is extremely low, 32 making FR a useful marker for targeted drug/gene delivery to tumors. Therefore, nano-carriers modied with FA can be efficiently uptaken by the cancer cells overexpressing FR via receptormediated endocytosis due to the high affinity between FA and FR. [33] [34] [35] [36] To investigate the utility of FPDP micelle as co-delivery carrier for shBeclin1 and DOX in cancer therapy, the cytotoxicity and FR-targeted cellular uptake of FPDP/DOX micelles was evaluated against FR À HepG2 cells and FR + HeLa cells in vitro.
Furthermore, shBeclin1 binding ability of FPDP micelles was investigated through gel retardation assay. More importantly, the antitumor efficacy of FPDP/DOX/shBeclin1 was assessed in HeLa cells and tumor-bearing nude mice to demonstrate that FPDP could be a promising candidate for prospective co-delivery of drugs and nucleic acids in cancer therapy.
Materials and methods

Materials
Folate (FA) was obtained from Sigma-Aldrich (St. Louis, USA). 1-Ethyl-3-(3-dimethyllaminopropyl) carbodiimide hydrochloride (EDC$HCl), N-hydroxysuccinimide (NHS) and propidium iodide (PI) were obtained from Aladdin Industrial Corporation. Lipofectamine™ 2000 was obtained from Invitrogen. All other reagents were of analytical grade and used without further purication. The shBeclin1 (sequence: GCTTCGCGCCGTAGTCTTA) and scrambled shRNA (shSCR) as a control (sequence: CTCAGGA-GAGGAGCCATTT) were purchased from Genecopoeia Technologies Inc.
Cell culture
Human liver cell (HL7702), human cervical cancer cell (HeLa) and human hepatoma cell (HepG2) were purchased from the Cell Bank of Shanghai Institute of Biochemistry and Cell Biology. Cells were cultured in Dulbecco's modied Eagle's medium (DMEM) supplemented with 10% (v/v) FBS under 5% CO 2 at 37 C for 24 h until they reached 80% conuence.
Synthesis of FPDP
As shown in Scheme 1, the amphiphilic bifunctional pullulan derivative (PDP) was synthesized according to our previous published procedure. 30 Then, 100 mg FA was dissolved in 50 mL carbonate buffer solution (1 M, pH 9.6), 65.8 mg EDC$HCl and 39.5 mg NHS was added. The mixture was stirred for 30 min at room temperature to activate the FA and PDP (366.6 mg) was added, the resultant mixture was stirred for further 24 h at 25 C. Aerwards, the reaction mixture was dialyzed against deionized water (MWCO, 10 kDa) for 72 h to wipe off small molecular weight impurities. Subsequently, the polymer FPDP solutions were lyophilized and stored at 4 C until further use.
FPDP structure and the degree of substitution of FA in the new polymer FPDP was determined by 1 H NMR (Varian INOVA400, USA).
Preparation of micelles
The blank FPDP micelles and FPDP/DOX micelles were prepared by dialysis method according to our previous published procedure.
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The preparation of FPDP/shBeclin1 complexes was achieved by electrostatic interaction. FPDP micelle solutions and shBeclin1 solutions in deionized water were mixed using gentle vortexing to form the FPDP/shRNA micelle complexes with different N/P ratios (weight of FPDP/ weight of shRNA).
2.5. Characterization and evaluation of micelles 2.5.1. Characterization of FPDP and FPDP/DOX micelles. Critical micellar concentration (CMC) of FPDP was determined using pyrene as the probe by uorescence spectroscopy (LS55, PerkinElmer).
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The particle size and zeta potential of FPDP, FPDP/DOX, FPDP/shBeclin1 and FPDP/DOX/shBeclin1 micelles were measured by dynamic light scattering (DLS) using Malvern Zetasizer NanoZS90 (Malvern instruments, UK). The morphology of micelles was observed by transmission electron microscopy (TEM, Tecnai G2 Spirit 120 kV). To evaluate the storage stability of the FPDP micelles, the particle size, PDI, and z potential were recorded for 60 h.
2.5.2. Assessing the DOX loading ability of FPDP. The DOX loading capacity (LC) and encapsulation efficiency (EE) were calculated as: LC% ¼ (weight of DOX in micelles)/(weight of polymeric micelles containing DOX) Â 100% and EE% ¼ (weight of DOX in micelles)/(weight of DOX fed initially) Â 100%.
2.5.3. Evaluation of FPDP/shBeclin1 complexes. The formation of complexes between FPDP micelles and shBeclin1 was conrmed by electrophoresis retardation assay. Firstly, a series of FPDP/shBeclin1 micelle complexes with different N/P ratios were formed. Then, 10 mL of FPDP/shBeclin1 complexes (shBeclin1 ¼ 1 mg per lane) were electrophoresed on a 1% agarose gel containing 0.2 mg mL À1 ethidium bromide in trisacetate-ethylene (TAE) diaminetetraacetic acid buffer at 140 V for 40 min. The gels were visualized and imaged under an ultraviolet transilluminator (G: BOX, Gene Company, Hong Kong, China).
Hemolysis assay for biocompatibility evaluation
The hemolytic ability of FPDP was evaluated by the method in our previous published procedure. 30 All measurements were performed in triplicate and the percentage of hemolysis was calculated as: hemolysis (%) ¼ (OD test À OD neg )/(OD pos À OD neg ) Â 100%, where OD test , OD neg and OD pos are the absorbance values of the tested sample, positive control (water) and negative control (PBS) separately.
In vitro drug release
The in vitro release proles of DOX from FPDP/DOX micelles were investigated by the dialysis method.
38 FPDP/DOX containing 0.2 mg of DOX was dissolved in 2 mL of PBS with different pH in a dialysis bag (MWCO, 10 kDa). Then, the dialysis bag was immersed in the corresponding pH PBS with shaking water bath at 37 C. At predetermined time intervals, withdraw 3 mL PBS and added the same volume of fresh PBS. The amount of DOX release were analyzed by uorescence measurement with excitation at 485 nm.
2.8.
In vitro cell culture studies 2.8.1. The cytotoxicity evaluation by MTT. The cytotoxicity was studied by the MTT assays using HL7702, HeLa and HepG2 cells. Briey, cells were seeded onto 96-well plate at 1.0 Â 10 4 cells per well in DMEM for 24 h. Then, the medium was replaced by fresh culture medium supplemented with 10% (v/v) FBS containing different tested samples of the desired concentration. Aer the cells were incubated for another 24 h or 48 h, MTT solution (0.5 mg mL À1 ) was added and further incubated for 4 h at 37 C. Subsequently, the medium was removed, and then 100 mL DMSO was added to dissolve the resulting purple crystals. The absorbance was measured at 570 nm and 630 nm using a microplate reader (Thermo Fisher Scientic). Cell viability was expressed as a percentage of the control culture value. Untreated cells in growth medium were used as the blank control. an OLYMPUS FV 1000 (OLYMPUS, Japan). For quantifying by FCM, the cells were rinsed with PBS to remove micelles that were not ingested by the cells and then digested with pancreatin, centrifuged, re-suspended in 200 mL PBS, and the uo-rescence intensity of DOX was analyzed by ow cytometer (FACSCanto, BD, USA). The competitive inhibition of free FA was applied for verifying the FR-targeted uptake mechanism of FPDP/DOX. Cells were exposed to free FA of different concentrations for 30 min to occupy the FRs of the cell surface before HeLa or HepG2 cells were treated with DOX and FPDP/DOX (4.0 mg mL À1 DOX-equivalent). For histological analysis, the HeLa cell bearing nude mice were sacriced on 21 days aer injection of tested samples, the major organs and tumors were collected and xed in 4% paraformaldehyde overnight. The paraffin embedded specimens were cut at 5 mmthick sections, de-waxed and rehydrated with xylene, a graded series of ethanol, and deionized water successively. 40 Finally, the xed sections were stained with H&E to assess histological alterations by OLYMPUS FV 1000 microscope (OLYMPUS, Japan).
2.9.3. Immunohistochemical analysis. For immunohistochemical analysis, tumor sections of paraffin-embedded were prepared and processed as described previously. 30, 41 Beclin1 protein expression in the sections was detected with an antiBeclin1 monoclonal antibody (Beclin1, 1 : 100 dilution, Proteintech, US). A Beclin1-positive reaction was indicated by a reddish-brown precipitate in the cytoplasm and analyzed by OLYMPUS FV 1000 microscope.
Statistical analysis
All the experiments were performed three times and the data were presented as means AE standard deviation (SD). Statistical analysis was conducted by using the Student's t-test and oneway analysis of variance analysis (ANOVA) by Origin version 9.0 soware (Northampton, USA). The difference was considered to be statistically signicant when P value < 0.05 (*) and P value < 0.01 (**). In this paper, the substitution degree of FA means the number of FA substituents for per 100 glucose unit, and the calculated substitution degree of FA in polymer FPDP was 2.2. Next, we investigated the self-assembly behavior and characterized FPDP micelles. CMC is an essential parameter related to the self-assembly ability of amphiphilic polymers. In this study, the CMC of FPDP micelles was determined to be 12.15 mg L À1 . The relatively low CMC value suggested that the micelles would retain structurally intact under extensively diluted conditions aer administration, which was advantageous to prolong blood circulation time and avoid the advanced leakage of drugs. Additionally, as shown in Fig. 1C , the particle sizes and zeta potentials of FPDP micelles didn't display obvious change aer FPDP micelles were incubated in 10% serum for different storage time, demonstrating that FPDP micelles have good storage stability. DLS measurement demonstrated that the mean size of blank FPDP micelles was 161.9 AE 1.45 nm, and the morphology of FPDP micelles observed by TEM (Fig. 1D) showed that blank FPDP micelles were uniformly dispersed and regularly spherical. Importantly, the positive surface zeta potential (30.33 AE 1.0 mV) of FPDP micelles would provide negatively-charged genebinding ability to the carrier.
Results and discussion
The biocompatibility of FPDP was rst assessed by the hemolysis test. As demonstrated in Fig. 1E , the hemolysis percentage caused by FPDP was still less than 5% even at higher FPDP concentration of 2.0 mg mL À1 . It was reported that hemolysis rate less than 5% is acceptable for biomedical 
Furthermore, the biocompatibility of FPDP was evaluated by its cytotoxicity against non-cancer cells (HL7702 cells) and two cancer cells (HeLa and HepG2 cells). As demonstrated in Fig. 1F , even at a high FPDP concentration (80 mg mL À1 ), the cell viability for all three tested cell lines still maintained higher than 85%, manifesting that blank FPDP micelles were non-toxic to HL7702, HeLa and HepG2 cells. In one word, the low cytotoxicity and hemolysis rate of FPDP copolymer makes it potential candidate as a safe material for gene/drug delivery.
DOX release behavior, FR-targeted cellular uptake and cytotoxicity of FPDP/DOX micelles in vitro
In this study, the FPDP/DOX micelles were prepared by dialysis method, and the drug loading capacity and encapsulation efficiency of the FPDP micelles for DOX were determined to be 7.4 AE 0.02% and 81.4 AE 0.17% separately. The in vitro release behavior of DOX was evaluated in PBS solutions with pH values of 7.4, 6.5, 5.0 respectively, and free DOX was used as the control. As shown in Fig. 2A , free DOX exhibited rapid release rate, and was completely released within 6 h. However, the FPDP/DOX micelles showed sustained release of DOX over 96 h, this phenomenon was due to the shielding effects of FPDP to DOX. On the other hand, the release rate of DOX from FPDP/DOX micelles increased remarkably in a pH-dependent manner. For example, at 48 h period, DOX release amount was only 54.47% at pH 7.4, but reached up to 60.59% and 71.07% at pH 6.0 and pH 5.0 respectively. One reason is that the protonation of the amino groups of PEI in FPDP under slightly acid environment changed the hydrophobic and hydrophilic properties of FPDP, which made the micelles to change from a compact sphere to an expanding shape, leading to the release of DOX more easily. Additionally, DOX was also protonated at acidic pH values, owing to its pK a of 8.3, 42 and the increasing solubility of protonated DOX in the micelles also induces easier drug release. It was reported that cancer cells intracellular environment is characterized by lower pH (4.5-7.2) as compared with normal cells. 43, 44 Thus, the pHsensitive release behavior is believed to prevent DOX release during the blood circulation 46 and is favorable for inducing sufficient release of DOX in the acidic endosome/lysosome compartment aer internalization by the cancer cells.
In 
ShRNA-binding and gene silencing in vitro
The positive surface zeta potential of micelles is important for gene-binding and internalizing into cancer cells. In the present study, the zeta potentials of FPDP/DOX, FPDP/shBeclin1 and FPDP/DOX/shBeclin1 micelles were 29.75 AE 0.4 mV, 28.28 AE 1.1 mV and 26.09 AE 1.1 mV respectively. To examine the ability of FPDP and FPDP/DOX micelles to bind shBeclin1 plasmid, agarose gel electrophoresis was performed to check the retardation of shBeclin1 plasmid mobility by FPDP and FPDP/DOX micelles. From Fig. 3A and Fig. 3B , it was found that both FPDP and FPDP/DOX could retard completely the electrophoretic mobility of shBeclin1 plasmid when the N/P reached to 10, pointing to an obvious binding ability to shBeclin1 plasmid. These results indicated that both FPDP and FPDP/DOX could form stable and compact complexes with shBeclin1 plasmid when mass ratio was equal to or higher than 10. Therefore, N/P ratio of 10 was used in the subsequent drug/gene co-delivery experiments.
Genetic studies have identied that in cancer cells exposed to antitumor agents, Beclin1 protein plays a crucial role in the autophagy activation by regulating the nucleation of autophagic vesicles to support cancer cell survival. 10 Therefore, concomitantly using shRNA to block the Beclin1 protein-relevant signaling pathway offers an effective solution to overcome the antiapoptotic defense of cancer cells caused by drug-induced autophagy. 45 In this study, the expression level of Beclin1 protein blocked by shBeclin1 was used to assess FPDP-mediated shBeclin1 delivery in HeLa cells by western blot experiment. As indicated in Fig. 3C and D, non- targeted shRNA (shSCR) showed no gene silencing effect on Beclin1 protein expression, but the targeted FPDP/shBeclin1 complexes almost completely knocked down the expression of Beclin1 protein. Free shBeclin1 also exerted no obvious inuence on the expression of Beclin1 protein, which was mainly due to the poor cellular uptake efficiency of free shBeclin1. 46 In a word, FPDP has the potential to be an idealistic shRNA delivery carrier for future gene silencing in the treatment of cancer.
Co-delivery of DOX and shBeclin1 in vitro
The experimental results above demonstrated that FPDP polymer holds the potential application for the targeted delivery of DOX and shBeclin1 into the FR + cancer cells separately. and dead HeLa cells owing to the fact that FPDP/DOX and FPDP/shBeclin1 could not enter the same cancer cells simultaneously. Taken together, these nding suggested that the codelivery of shBeclin1 and DOX with FPDP micelles enabled the silence of Beclin1 and suppressed the autophagy caused by DOX chemotherapy, consequently make cancer cells more sensitive to DOX, and thus induce cell-apoptosis more efficiently. Additionally, the synergetic antitumor effect of DOX and shBeclin1 was further investigated by evaluating the cytotoxicity with MTT method. As displayed in Fig. 4B , aer incubation for 24 h, blank FPDP, free shSCR and FPDP/shSCR treated HeLa cells showed no obvious toxicity compared with control group. Whereas, FPDP/DOX/shBeclin1 emerged signicantly higher cytotoxicity compared with other treatment, demonstrating that FPDP micelles could achieve efficiently co-delivery of shBeclin1 and DOX into the same cells to induce higher cell apoptosis rate and improve the anticancer effect of DOX through the blockade of autophagy process. The positive antitumor effect of FPDP/DOX/shBeclin1 in vitro encouraged us to further investigate the synergistic antitumor therapeutic efficacy of FPDP/DOX/shBeclin1 in HeLa tumorbearing BALB/c nude mice. It could be observed in Fig. 5A that FPDP/DOX/shBeclin1 micelles displayed the highest efficiency in inhibiting the tumor growth. Fig. 5B showed that the tumors in PBS and FPDP/shBeclin1 group grew quickly, the ; shSCR and shBeclin1 concentration was at 1.87 mg mL
À1
, N/P ¼ 10. average tumor volume reached approximately 1300 mm 3 and 1200 mm 3 within 21 days respectively, indicating that the knockdown of Beclin1 gene alone exerted no effect on inhibiting the growth of tumors. The mice treated with other micelles (FPDP/DOX, FPDP/DOX + FPDP/shSCR, FPDP/DOX + FPDP/ shBeclin1, and PDP/DOX/shBeclin1) showed gradual tumor growth at various rates. As we expected, the tumors in FRtargeted FPDP/DOX/shBeclin1 group exhibited almost no growth during the whole therapeutic process. Moreover, to investigate the role of Beclin1 knockdown in synergistic antitumor efficacy, we sectioned tumor xenogras and analyzed the expression level of shBeclin1 protein by immunohistochemistry. In Fig. 5C , a Beclin1-positive reaction was indicated by a reddish-brown precipitate in the cytoplasm and deeper color means more Beclin1 protein was expressed. FPDP/DOX group showed obvious deeper reddish-brown color in the cytoplasm compared with PBS group, due to the DOXinduced autophagy activation, which result in the upregulation of Beclin1 protein expression. In contrast, owing to the knockdown effect of shBeclin1, the expression of Beclin1 protein in FPDP/DOX/shBeclin1 group was markedly downregulated, and also was lower than that in FPDP/shBeclin1 and PDP/DOX/shBeclin1 micelles group, demonstrating the excellent tumor targeting ability of FPDP micelles.
As is well-known, most chemotherapeutic agents can cause severe side effects such as organ toxicity and weight loss, thus compromising the therapeutic efficacy. From Fig. 5D , we can see that within 21 days the body weight of mice treated with FPDP/ DOX/shBeclin1 showed gradually increased, suggesting low toxicity of injected nano-complexes. Fig. 6 showed HE staining on heart, lung, liver, spleen and kidney, in comparison with the organs in control PBS group, no signicant histopathological damages were observed in the tissues of the organ treated with micelles-treated groups. Therefore, these results demonstrated that the co-delivery of DOX/shBeclin1 by FPDP micelles can not only enhance the anti-tumor efficacy of DOX through overcoming the drug-resistance caused by DOX-induced autophagy, but also reduced its systemic toxicity, indicating that FPDP/DOX/ shBeclin1 will be a promising therapeutic method for cancer therapy in the future.
Targeting ability of FPDP in vivo
The targeting ability of FPDP nanocomplexes in tumor-bearing mice in vivo was also checked, and displayed in Fig. 7 . In free DOX-treated group, the DOX intensity in tumor was weak and appeared at several sites, meaning that free DOX can distribute in the whole body of mice and be metabolized quickly. However, 
Conclusions
In summary, we synthesized a novel FR-targeted copolymer FPDP for effective targeted co-delivery of DOX and shBeclin1 for improving the anticancer effect of DOX through the blockade of autophagy process for the rst time. FPDP exhibited good biocompatibility and excellent loading capacities for both DOX and shBeclin1. Meanwhile, FPDP/DOX micelles could effectively target FR + cancer cells via the FR mediated endocytosis process.
Most importantly, the FPDP micelles could efficiently co-deliver shBeclin1 and DOX into the cytoplasm of the same HeLa cells, exhibiting the strongest synergistic antitumor efficacy compared with FPDP/DOX micelles or FPDP/shBeclin1 alone. Excitedly, in HeLa-bearing nude mice, FR-targeted FPDP/DOX/ shBeclin1 could be delivered to the tumor site, and suppressed cancer growth more effectively than delivery of either DOX or shBeclin1 separately in cancer therapy. This study indicated the great potential of the FPDP to serve as an effective carrier for enhancing the intracellular co-delivery of DOX and therapeutic shBeclin1 in cancer cells overexpressing FR to improve the anticancer effect of DOX through the blockade of autophagy process in cancer therapy.
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